

TABLE. Immunizations for Protection Against Selected Respiratory Viruses, 2023–2024

Target Disease	Required for Military Personnel	Recommended Age Group	Available Vaccine Products Within MHS	Timing of Vaccination
Influenza	Yes	≥ 6 months	Fluzone Quadrivalent and High-Dose Quadrivalent (Sanofi Pasteur), ^a Afluria Quadrivalent, Flucelvax Quadrivalent, Fluad Quadrivalent (Seqirus), ^a Fluarix Quadrivalent and Flulaval Quadrivalent (GSK) ^a	September–October preferred
COVID-19	No	≥ 6 months	Comirnaty (Pfizer), ^a Spikevax (Moderna), ^a Novavax ^a Monovalent	≥2 months after most recent dose of COVID-19 vaccine
RSV, adult ^b	No	≥ 60 years	Abrysvo preF (Pfizer), ^a Arexvy preF (GSK) ^a	When vaccine is available locally
RSV, pediatric ^c	N/A	Pregnant persons	Abrysvo (Pfizer) ^{a,c}	32-36 weeks prenatally
RSV, pediatric ^c	N/A	0-8 months 8-19 months ^d	Beyfortus mAb (Sanofi, Astra-Zeneca) ^{a,c}	Before start of RSV season ^e

Note: Per ACIP General Best Practice guidelines, all vaccines can be given with other vaccines.

Abbreviations: MHS, Military Health System; RSV, Respiratory Syncytial Virus; preF: Recombinant-stabilized prefusion F protein; mAb, Monoclonal antibody; ACIP, Advisory Committee on Immunization Practices.

^a Product and company names are provided for identification only and do not imply endorsement.

^b Recommended with shared clinical decision-making.

^c Using shared clinical decision-making, either prenatal Abrysvo or Beyfortus is recommended for prevention among infants 0-8 months of age entering their first RSV season.

^d Second dose only or specific high-risk infants entering their second RSV season.

^e In most of the continental U.S., from October through end of March.